[go: up one dir, main page]

RU2018108202A3 - - Google Patents

Download PDF

Info

Publication number
RU2018108202A3
RU2018108202A3 RU2018108202A RU2018108202A RU2018108202A3 RU 2018108202 A3 RU2018108202 A3 RU 2018108202A3 RU 2018108202 A RU2018108202 A RU 2018108202A RU 2018108202 A RU2018108202 A RU 2018108202A RU 2018108202 A3 RU2018108202 A3 RU 2018108202A3
Authority
RU
Russia
Application number
RU2018108202A
Other versions
RU2740919C2 (ru
RU2018108202A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58101064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018108202(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2018108202A publication Critical patent/RU2018108202A/ru
Publication of RU2018108202A3 publication Critical patent/RU2018108202A3/ru
Application granted granted Critical
Publication of RU2740919C2 publication Critical patent/RU2740919C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Medicinal Preparation (AREA)
RU2018108202A 2015-08-24 2016-08-24 Способы лечения синдрома леннокса-гасто с использованием фенфлурамина RU2740919C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209090P 2015-08-24 2015-08-24
US62/209,090 2015-08-24
PCT/US2016/048470 WO2017035267A1 (en) 2015-08-24 2016-08-24 Methods of treating lennox-gastaut syndrome using fenfluramine

Publications (3)

Publication Number Publication Date
RU2018108202A RU2018108202A (ru) 2019-09-26
RU2018108202A3 true RU2018108202A3 (ru) 2020-01-20
RU2740919C2 RU2740919C2 (ru) 2021-01-21

Family

ID=58101064

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018108202A RU2740919C2 (ru) 2015-08-24 2016-08-24 Способы лечения синдрома леннокса-гасто с использованием фенфлурамина

Country Status (22)

Country Link
US (4) US20170056344A1 (ru)
EP (2) EP4397372A3 (ru)
JP (1) JP6895949B2 (ru)
KR (3) KR20180054584A (ru)
CN (3) CN115350168A (ru)
AU (1) AU2016312526B2 (ru)
BR (1) BR112018002046A2 (ru)
CA (1) CA2993665C (ru)
DK (1) DK3340971T3 (ru)
ES (1) ES2979034T3 (ru)
FI (1) FI3340971T3 (ru)
HR (1) HRP20240508T1 (ru)
HU (1) HUE066912T2 (ru)
IL (1) IL257276B (ru)
LT (1) LT3340971T (ru)
MX (1) MX389927B (ru)
PL (1) PL3340971T3 (ru)
PT (1) PT3340971T (ru)
RU (1) RU2740919C2 (ru)
SI (1) SI3340971T1 (ru)
WO (1) WO2017035267A1 (ru)
ZA (1) ZA201800499B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543805A (ja) 2010-11-12 2013-12-09 ナイアガラ・ボトリング・エルエルシー 軽量ボトルを加工するための伸長仕上げされたプリフォーム
US10647465B2 (en) 2010-11-12 2020-05-12 Niagara Bottling, Llc Perform extended finish for processing light weight ecologically beneficial bottles
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
MX391077B (es) 2015-12-22 2025-03-21 Zogenix International Ltd Composiciones de fenfluramina y métodos de preparación de las mismas.
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
KR20190142364A (ko) * 2017-05-09 2019-12-26 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
WO2019216919A1 (en) * 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3820459A1 (en) * 2018-07-10 2021-05-19 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
US11597556B2 (en) 2018-07-30 2023-03-07 Niagara Bottling, Llc Container preform with tamper evidence finish portion
CA3117868A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US20220133652A1 (en) * 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
JP2022548892A (ja) * 2019-09-17 2022-11-22 ゾゲニクス インターナショナル リミテッド てんかん患者をフェンフルラミンで治療する方法
US20210299064A1 (en) * 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
RU2007148444A (ru) * 2005-05-25 2009-06-27 Янссен Фармацевтика Н.В. (Be) Педиатрическая композиция топирамата
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
GB0515090D0 (en) * 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
PE20110852A1 (es) * 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011132171A1 (en) * 2010-04-23 2011-10-27 Piramal Life Sciences Limited Nitric oxide releasing prodrugs of therapeutic agents
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SI3035926T1 (sl) 2013-08-19 2020-11-30 The Regents Of The University Of California Spojine in postopki za zdravljenje epileptičnih motenj
JP6774402B2 (ja) 2014-09-29 2020-10-21 ゾゲニクス インターナショナル リミテッド 薬物供給管理用の管理システム

Also Published As

Publication number Publication date
ES2979034T3 (es) 2024-09-23
JP6895949B2 (ja) 2021-06-30
CN115350168A (zh) 2022-11-18
RU2740919C2 (ru) 2021-01-21
CN115192575A (zh) 2022-10-18
EP4397372A3 (en) 2024-09-11
KR102481631B1 (ko) 2022-12-27
KR20220025927A (ko) 2022-03-03
US20240245631A1 (en) 2024-07-25
US20170056344A1 (en) 2017-03-02
FI3340971T3 (fi) 2024-06-10
ZA201800499B (en) 2018-12-19
EP4397372A2 (en) 2024-07-10
AU2016312526B2 (en) 2021-09-09
CA2993665A1 (en) 2017-03-02
PT3340971T (pt) 2024-06-05
MX2018001435A (es) 2018-04-20
US20240238222A1 (en) 2024-07-18
RU2018108202A (ru) 2019-09-26
EP3340971A4 (en) 2019-05-01
EP3340971A1 (en) 2018-07-04
KR20180054584A (ko) 2018-05-24
BR112018002046A2 (pt) 2018-09-18
HRP20240508T1 (hr) 2024-07-05
US20200253895A1 (en) 2020-08-13
CN108135865A (zh) 2018-06-08
KR102615486B1 (ko) 2023-12-19
AU2016312526A1 (en) 2018-02-22
KR20230005426A (ko) 2023-01-09
HUE066912T2 (hu) 2024-09-28
EP3340971B1 (en) 2024-03-13
JP2018525418A (ja) 2018-09-06
IL257276B (en) 2022-06-01
IL257276A (en) 2018-03-29
SI3340971T1 (sl) 2024-05-31
LT3340971T (lt) 2024-04-25
DK3340971T3 (da) 2024-05-27
MX389927B (es) 2025-03-20
WO2017035267A1 (en) 2017-03-02
CA2993665C (en) 2023-03-07
PL3340971T3 (pl) 2024-07-15

Similar Documents

Publication Publication Date Title
RU2018108202A3 (ru)
BR112017027855A2 (ru)
BR112018005126A2 (ru)
AU2022228198B1 (ru)
BR112018003994A2 (ru)
BR112017027537A2 (ru)
BE2015C047I2 (ru)
BE2015C044I2 (ru)
BR0009994B1 (ru)
BR0002694B1 (ru)
CN303069598S (ru)
CN303068877S (ru)
CN303068626S (ru)
BR0002435B1 (ru)
BR9909676B1 (ru)
BR0002402B1 (ru)
BR0002033B1 (ru)
BR0001810B1 (ru)
BR0001684B1 (ru)
BR0001536B1 (ru)
BR0000763F1 (ru)
BR0316391B1 (ru)
BR0313340B1 (ru)
BR0300367B1 (ru)
CN303071086S (ru)